Ticagrelor Use in Stroke Patients: Past, Present, and Future
Rahul Chandra,Harneel Saini,Russell Cerejo,Ashis Tayal,Konark Malhotra
DOI: https://doi.org/10.2147/VHRM.S266968
2021-06-15
Vascular Health and Risk Management
Abstract:Rahul Chandra, Harneel Saini, Russell Cerejo, Ashis Tayal, Konark Malhotra Department of Neurology, Allegheny Health Network, Pittsburgh, PA, USA Correspondence: Konark Malhotra Department of Neurology, Allegheny Health Network, Pittsburgh, PA, USA Tel +1- 412-359-8841 Fax +1- 412-442-2115 Email Antiplatelet medications are the mainstay for secondary stroke treatment. Aspirin, clopidogrel, and aspirin-dipyridamole are commonly used antiplatelet medications. Other antiplatelet medications such as ticagrelor and prasugrel have been majorly used in cardiovascular or neuro-interventional specialties. Recent studies have paved a way to their use in secondary stroke prevention. In this review, we have briefly discussed the pharmacology of ticagrelor, published literature in cardiology and stroke trials, use of ticagrelor among patients with ischemic strokes, and compared its efficacy, limitations and side-effects with other antiplatelet medications. Keywords: Ticagrelor, stroke, clopidogrel, platelet inhibition Ticagrelor is a potent, direct-acting antiplatelet agent that reversibly binds and inhibits platelet adenosine diphosphate P2Y12 receptors. 1 In comparison to other P2Y12 antagonists, ticagrelor does not require conversion from a prodrug to an active formulation. Ticagrelor and its metabolite are equipotent and achieve peak concentration within 2–3 days of its last dose. Due to its higher affinity for protein, ticagrelor maintains a linear pharmacokinetics. 2 Additionally, Ticagrelor is dosed twice-daily which allows for a more consistent inhibition of platelets over a 24-hour period. 2 The use of ticagrelor in ischemic events was initially studied in patients with coronary artery disease (CAD). The Dose confIrmation Study assessing anti-platelets Effects of AZD6140 vs clopidogRel in non–ST-segment Elevation myocardial infarction (NSTEMI), DISPERSE, was an international, randomized, double-blinded, prospective trial that evaluated the efficacy of ticagrelor and clopidogrel in patients with NSTEMI. 4 In comparison to clopidogrel, ticagrelor showed a significant reduction in the rates of vascular deaths without an increase in the overall rate of major bleeding in patients with acute coronary syndrome regardless of ST-segment elevation. The primary endpoint looked at the rate of major and/or minor bleeding complications. The primary endpoint was 8.1% in the clopidogrel group and 9.8% in the ticagrelor group. A major limitation of the trial involved the pathophysiological differences between the effect of ticagrelor and clopidogrel on inflammation and endothelial dysfunction in STEMI patients. The Platelet Inhibition and Patient Outcomes (PLATO) was an international, randomized trial that compared the efficacy of platelet inhibition of ticagrelor against prasugrel in patients with STEMI who underwent percutaneous coronary intervention. 5 The primary endpoint was residual platelet reactivity 2 hours after a loading dose, while the secondary endpoints were percentage of high residual platelet reactivity, acute stent thrombosis and in-hospital bleeding after thrombolysis for MI. The study showed prasugrel was non-inferior to ticagrelor for residual platelet inhibition at 2 hours after the loading dose. PLATO trial entailed a similar limitation involving the differential effect of ticagrelor and prasugrel among STEMI patients. The Prior Heart Attack Using ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54), was an international, randomized, double-blinded, placebo-controlled trial which evaluated the efficacy of ticagrelor against a placebo among patients with ACS who underwent coronary artery bypass grafting (CABG). 7 The primary outcome was graft occlusion at 3 months post CABG with secondary endpoints of MI, stroke and bleeding. Although the study was prematurely terminated, it did show a synergistic effect of ticagrelor with low-dose aspirin that reduced the risk of major adverse cardiovascular events. Furthermore, ticagrelor significantly reduced the risk of stroke, thus paving the way for its study and use among acute ischemic stroke (AIS) patients. A major limitation of the trial involved a lack of follow-up data that required extrapolation of clinical data at the time of the MI to estimate the trial eligibility. The Examining Use of ticagrelor in Peripheral Artery Disease (EUCLID) trial was a double blinded, randomized prospective trial which evaluated the efficacy of clopidogrel against ticagrelor in patients with symptomatic peripheral vascular disease with a median follow-up of 30 months. 6 Th -Abstract Truncated-